Phase II
London-based ReViral announced the completion of a Series B financing worth $55 million. The financing was jointly led by New Leaf Venture Partners and Novo Ventures, part of Novo Holdings, with new investors Perceptive Advisors. Existing investors also participated, including Andera Partners, OrbiMed and Brace Pharma Capital.
Although Pfizer’s second-quarter financials exceeded expectations, with its adjusted earnings per share coming in at $0.81 compared to a forecast of $0.74, in its reporting there were a few changes to its pipeline.
Active Biotech, based in Lund, Sweden, announced that its laquinimod failed to meet its primary endpoint in its Phase II clinical trial for Huntington’s disease.
The U.S. Food and Drug Administration (FDA) approved New York-based Progenics Pharmaceuticals’ New Drug Application (NDA) for Azedra for adult and pediatric patients 12 years and older with iobenguane scan positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma who require systemic anticancer therapy. It is the first and only therapy approved for these indications.
Astex Pharmaceuticals, a member of the Otsuka group of companies, and Otsuka Pharmaceutical, indicated their guadecitabine (SGI-110) missed its co-primary endpoints in acute myeloid leukemia (AML).
BioLineRx, based in Tel Aviv, Israel, and Merck & Co, based in Kenilworth, New Jersey, announced they are expanding their immuno-oncology collaboration.
Liquidia Technologiesnlaunched a successful initial public offering on July 25, raising $50 million. Neal Fowler, the company’s chief executive officer, and Kevin Gordon, Liquidia’s president and chief financial officer, took time out to talk with BioSpace about the company and where it’s headed.
Although the overall stock market has been a bit jittery as the result of a trade war, biotech stocks have been surprisingly steady—at least in comparison to their usual volatility.
The FDA notified Sarepta Therapeutics that its Phase I/IIa Micro-Dystrophin Gene Therapy Trial for Duchenne muscular dystrophy (DMD) has been placed on a clinical hold because of contamination of its therapeutic.
Many analysts and investors were holding their breaths, waiting to see what Biogen would say at yesterday’s second-quarter financial report. The financials weren’t the focus, however, but what the Cambridge, Massachusetts biotech had to say about its pipeline, especially for Alzheimer’s disease, was.
PRESS RELEASES